ucsf banner
Helen Diller Family Compr Cancer Ctr
CHARLES A. LINKER, MD

Krishnamurthi Endowed Chair in Hematologic Malignancies, UCSF
Director, Adult Leukemia & BMT Program, UCSF
Co-Leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center

CONTACT

(415) 353-2421 (appts)
(415) 353-2467 (fax)

Box 0324, UCSF; San Francisco, CA 94143-0324

additional websites:

UCSF Physician Referral Directory

EDUCATION

Harvard College, BA, 1970, Biochemistry
Stanford University School of Medicine, MD, 1974, Medicine
Stanford University Hospital, Internship, 1974-75, Medicine
Stanford University Hospital, Residency, 1975-78, Medicine
University of California, San Francisco, Fellowship, 1978-81, Hematology/Oncology

PROFESSIONAL EXPERIENCE

1981-1987

Assistant Clinical Professor of Medicine, University of California, San Francisco

1981-1990

Director, Pheresis Service, University of California, San Francisco

1987-1993

Associate Clinical Professor of Medicine, University of California, San Francisco

1993-present

Clinical Professor of Medicine, University of California, San Francisco

1990-present

Director, Adult Leukemia and Bone Marrow Transplant Program, University of California, San Francisco

SELECTED PUBLICATIONS

Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker, CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high dose therapy and bone marrow transplants in adults with chronic myelogenous leukemia in chronic phase. Leukemia Res 23:817-826 (1999).

Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker, CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in first remission . Leukemia Res 23:709-718 (1999).

Nash RA, Kursrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum FR, Champlin R. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 6(1): 25-34 (2000).

Linker CA, Ries CA, Damon LE, Rubin A, Case D, Crilley P, Topolsky D, Brodsky I, Zamkoff K, Wolf J. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biology of Blood and Marrow Transplantation 6(1):50-57 (2000).

Damon LE, Wolf JL, Rugo HS, Gold E, Ries CA, Zander AR, Tracy M, Cecchi G, Linker CA: High-dose cyclophosphamide, thiotepa and mitoxantrone (CTM) with hematopoietic stem cell rescue for breast cancer. Bone Marrow Transplant 26:257-268 (2000).

Linker CA Thrombopoetin in the treatment of acute myeloid leukemia and in stem cell transplantation Sem Hematol 37 Suppl 4: 35-40 (2000).

Damon LE, Hu WW, Stockerl-Goldstein KE, Blume K, Wolf J, Gold E, Cecchi G, Irwin D Glaspy J, Territo M, Mason JR, Linker CA. High-dose chemotherapy and stem cell rescue for breast Cancer: experience in California. Biology of Blood and Marrow Transplantation 6: 496-505 (2000)

Martin TM, Linker CA. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. Medical Clinics of North America 15:121-143 (2001).

DJ Winston, JH Antin, SN Wolf, BE Bierer, T Small, KB Miller, C Linker, et al.: A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. BMT 28: 187-196 (2001).

Miller CB, Rowlings PA, Zhang M, Jones RJ, Piantadosi S, Keating A, Armitage JO, Calderwood S, Harris RE, Klein JP, Lazarus HM, Linker CA, Sobocinski KA, Weisdorf D, Horowitz MM. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. J Exp. Med, (in press).

Johnston LJ, Damon LE, Ries CA, Rugo HS, Linker CA. Treatment of high-risk acute leukemia with idarubicin, high-dose etoposide and high-dose ara-C (IDEA): A randomized study of schedule dependency of etoposide. Leukemia (in press).

Linker CA, Anderlini P, Bensinger W, Christiansen N, Fat J, Goodnough LT, Herzig R, Lynch JP, Somlo G, Weaver C. A randomized phase II trial of recombinant human thrombopoietin in patients undergoing autologous stem cell transplantation (submitted).

Rugo HS, Ries CA, Levitt LJ, O'Donnell M, Forman SJ, Slovak M, Linker CA. Risk of myeloid relapse from intensive cyclical chemotherapy containing tenoposide for adult acute lymphoblastic leukemia (submitted).

Linker CA, Damon LE, Ries CA, Navarro W, Case D, Wolf J. Autologous stem cell transplant for advanced acute myeloid leukemia. BMT 2001 (in press).

Book Chapters

Benz C, Linker CA: Hematology and Oncology in Review of General Internal Medicine: A Self-Assessment Manual, Smith and Wyngarden, Eds., 3rd ed. (1985).

Embury SH, Linker CA. Hematologic Emergencies in Current Emergency Diagnosis and Treatment, Mills, Ho, Slaber, Trunkey, Eds., 4th ed. (1992).

Linker CA, Congenital Disorders of Hemostasis in Blood Disorders in Pregnancy, Laros, Ed. (1986).

Linker CA. Blood In Current Medical Diagnosis and Treatment, Tierney LM, McPhee SJ, Papadakis MA, Eds.,Appleton and Lange, 39th Edition (2000)

1/11/02

This site will look much better in a browser that supports web standards, but it is accessible to any browser or Internet device. Please upgrade your browser.